These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30606462)

  • 1. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.
    Quintel BK; Thomas A; Poer DeRaad DE; Slifka MK; Amanna IJ
    Vaccine; 2019 Jul; 37(30):4214-4221. PubMed ID: 30606462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.
    Pinto AK; Richner JM; Poore EA; Patil PP; Amanna IJ; Slifka MK; Diamond MS
    J Virol; 2013 Feb; 87(4):1926-36. PubMed ID: 23221549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
    Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
    Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine.
    Poore EA; Slifka DK; Raué HP; Thomas A; Hammarlund E; Quintel BK; Torrey LL; Slifka AM; Richner JM; Dubois ME; Johnson LP; Diamond MS; Slifka MK; Amanna IJ
    Vaccine; 2017 Jan; 35(2):283-292. PubMed ID: 27919629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice.
    Venter M; van Vuren PJ; Mentoor J; Paweska J; Williams J
    Vaccine; 2013 Aug; 31(37):3856-62. PubMed ID: 23820079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.
    Woods CW; Sanchez AM; Swamy GK; McClain MT; Harrington L; Freeman D; Poore EA; Slifka DK; Poer DeRaad DE; Amanna IJ; Slifka MK; Cai S; Shahamatdar V; Wierzbicki MR; Amegashie C; Walter EB
    Vaccine; 2019 Jul; 37(30):4222-4230. PubMed ID: 30661836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.
    Samina I; Havenga M; Koudstaal W; Khinich Y; Koldijk M; Malkinson M; Simanov M; Perl S; Gijsbers L; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2007 Nov; 25(49):8338-45. PubMed ID: 17977629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-structural protein 1 (NS1) antibody-based assays to differentiate West Nile (WN) virus from Japanese encephalitis virus infections in horses: effects of WN virus NS1 antibodies induced by inactivated WN vaccine.
    Kitai Y; Kondo T; Konishi E
    J Virol Methods; 2011 Jan; 171(1):123-8. PubMed ID: 20974180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.
    Seino KK; Long MT; Gibbs EP; Bowen RA; Beachboard SE; Humphrey PP; Dixon MA; Bourgeois MA
    Clin Vaccine Immunol; 2007 Nov; 14(11):1465-71. PubMed ID: 17687109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
    Grosenbaugh DA; Backus CS; Karaca K; Minke JM; Nordgren RM
    Vet Ther; 2004; 5(4):251-7. PubMed ID: 15719324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.
    Gershoni-Yahalom O; Landes S; Kleiman-Shoval S; Ben-Nathan D; Kam M; Lachmi BE; Khinich Y; Simanov M; Samina I; Eitan A; Cohen IR; Rager-Zisman B; Porgador A
    Immunology; 2010 Aug; 130(4):527-35. PubMed ID: 20331473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.
    Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC
    Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine.
    Bowen RA; Bosco-Lauth A; Syvrud K; Thomas A; Meinert TR; Ludlow DR; Cook C; Salt J; Ons E
    Vaccine; 2014 Sep; 32(42):5455-9. PubMed ID: 25131745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. West Nile Virus: is a vaccine needed?
    Martina BE; Koraka P; Osterhaus AD
    Curr Opin Investig Drugs; 2010 Feb; 11(2):139-46. PubMed ID: 20112163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.